Most of us walk around with a silent companion we don’t even know about. Toxoplasma gondii (T. gondii) is a microscopic parasite that has found its way into roughly one-third of the global population. You might have picked it up from undercooked meat, contaminated water, or your cat’s litter box. For most, it’s no big deal—your immune system keeps it in check, and you never notice a thing.
But what if that “silent” infection is doing more than we thought? What if it’s quietly nudging your mood, dialing up your anxiety, and reshaping how your brain handles stress?
Recent research has begun to pull back the curtain on this connection, and the findings are equal parts fascinating and unsettling. Scientists are discovering that chronic T. gondii infection doesn’t just sit idle in the brain—it triggers a cascade of immune and metabolic changes that can alter behavior. And now, a breakthrough study has identified a specific molecular pathway that appears to drive this anxiety-inducing effect. Even more intriguing? There may be a way to block it.
The Parasite in the Room
Let’s start with the basics. Toxoplasma gondii is a neurotropic parasite, meaning it has a particular affinity for the brain. Once inside, it forms cystic structures—think of them as tiny, dormant capsules—that can persist for years, possibly for life. The Wh6 strain, predominant in China, is especially good at establishing this kind of chronic infection.
For a long time, researchers suspected that T. gondii might influence behavior. Anecdotal reports and epidemiological studies have linked T. gondii seropositivity (meaning antibodies to the parasite are detectable in the blood) with higher rates of anxiety disorders in humans. The same pattern shows up in lab mice: chronically infected mice become more hesitant, less exploratory, and show clear signs of anxiety-like behavior.
But “linked to” and “causes” are very different things. The big unanswered question was: how? How does a parasite hiding out in brain tissue actually change how a host feels and acts?
It’s Not Just in Your Head—It’s in Your Amygdala
To understand what’s happening, you have to zoom in on a tiny region deep in the brain called the amygdala. This is ground zero for emotional processing—fear, anxiety, the gut-level sense that something isn’t quite right. It’s also one of the places where T. gondii loves to hang out.
When researchers looked at the amygdala in mice chronically infected with the Wh6 strain, they found a mess of neuroinflammation. The brain’s immune cells, called microglia, were in a state of chronic activation—basically, they were stuck in “alarm” mode. Instead of quietly maintaining the brain environment, they were pumping out pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β.
This matters because neuroinflammation isn’t just a side effect—it’s a driver of anxiety. Those inflammatory molecules interfere with how neurons communicate, and they particularly mess with serotonin (5-HT), the neurotransmitter most famously associated with mood regulation. Here’s the kicker: inflammation ramps up an enzyme called IDO (indoleamine 2,3-dioxygenase), which breaks down tryptophan—the precursor to serotonin—before it can be turned into 5-HT. Less tryptophan available means less serotonin, and that imbalance is tightly linked to anxiety and depression.
So the chain of events started to come into focus: infection → neuroinflammation → IDO upregulation → serotonin depletion → anxiety-like behavior. But the story still had missing pieces.
Enter the Metabolic Twist
Here’s where things get interesting. In recent years, immunologists have been paying a lot of attention to a gene called Acod1 (also known as Irg1). This gene codes for an enzyme that sits in the Krebs cycle—the classic “energy factory” of the cell—and converts a molecule called cis-aconitate into itaconate.
Itaconate has a Jekyll-and-Hyde personality. On one hand, it’s a potent anti-inflammatory metabolite. It can dial down immune overreaction by activating a protective pathway called Nrf2/Keap1. On the other hand, when things go wrong, the very systems meant to protect the brain might end up contributing to pathology.
In the context of chronic T. gondii infection, researchers found that the Acod1/itaconate axis was significantly upregulated in the amygdala. That made sense—the brain was trying to fight inflammation. But was this helpful? Or was it part of the problem?
To find out, they turned to mice that were genetically modified to lack the Acod1 gene entirely. These “knockout” mice were unexpectedly anxious—even without any infection. The implication was clear: Acod1/itaconate is normally protective against anxiety. When it’s missing, anxiety bubbles up.
But here’s the twist: when these knockout mice were given supplemental itaconate (in the form of a cell-permeable derivative called dimethyl itaconate, or DI), their anxiety-like behavior improved. That suggested that itaconate—or something like it—could be harnessed as a therapy.
The Therapeutic Pivot: Can We Block Infection-Induced Anxiety?
This was the pivotal moment in the research. If supplementing itaconate could help genetically prone mice, could it also help mice whose anxiety was triggered by chronic T. gondii infection?
The answer appears to be yes—on multiple fronts.
Prevention: When mice were given DI before being infected with T. gondii, they were strikingly resilient. They didn’t develop the usual anxiety-like behaviors. Their microglia didn’t go into overdrive. Their inflammatory cytokine levels stayed relatively normal. It was as if DI had “primed” the brain to handle the infection without tipping into anxiety.
Treatment: Even more impressively, DI worked when given after the infection was already established. Mice that had been infected for four weeks—long enough for cysts to form and anxiety to set in—showed measurable improvements after starting DI treatment. They became more exploratory in open-field tests. They spent more time in the open arms of elevated plus mazes (a standard test for anxiety in rodents). Their brain inflammation cooled down, IDO levels dropped, and serotonin levels rebounded.
Crucially, DI didn’t seem to kill the parasite or reduce the number of brain cysts. The infection was still there. But the behavioral and neurological damage was significantly reduced. That’s a huge distinction. It means the parasite itself might not be the direct cause of anxiety—it’s the immune-metabolic fallout from how the brain responds to the parasite.
Connecting the Dots: The Nrf2 Pathway
How exactly does DI work? The research points to a pathway called Nrf2/Keap1. Think of Nrf2 as a master switch for antioxidant and anti-inflammatory defenses. Under normal conditions, Nrf2 is kept in check by a protein called Keap1. But when itaconate (or DI) shows up, it modifies Keap1 in a way that releases Nrf2, allowing it to go into the nucleus and turn on a whole suite of protective genes.
When researchers tested this in microglial cells (the brain’s immune cells) infected with T. gondii, they found that DI activated Nrf2 and simultaneously suppressed the M1 “pro-inflammatory” polarization of microglia. M1-polarized microglia are the ones that pump out TNF-α, IL-6, and IL-1β—the exact cytokines that drive neuroinflammation and, ultimately, anxiety.
To double-check this mechanism, the researchers used sulforaphane, a known Nrf2 activator derived from broccoli sprouts. Sulforaphane mimicked the effects of DI, reducing inflammatory cytokine expression and preventing M1 polarization. That was a strong hint that the Nrf2 pathway is the real deal—the central mechanism through which itaconate exerts its anxiety-reducing effects.
Why This Matters Beyond T. gondii
You might be thinking: “Okay, but I don’t have a parasitic infection (probably). Why should I care?”
Here’s the broader implication: the neuroinflammatory mechanism uncovered in this study isn’t unique to T. gondii. Neuroinflammation is a common thread in many forms of anxiety and depression—whether triggered by chronic stress, genetic predisposition, autoimmune disease, or environmental toxins. In all these cases, microglia go rogue, pro-inflammatory cytokines flood the brain, and the serotonin system gets disrupted.
If the Acod1/itaconate axis can be harnessed to modulate that inflammatory response, it might represent a entirely new class of anti-anxiety therapy—one that doesn’t target neurotransmitters directly (like SSRIs) but instead addresses the underlying immune dysfunction that’s driving the mood disorder in the first place.
That’s a paradigm shift. And it’s one that could eventually benefit people whose anxiety doesn’t respond to conventional treatments.
The Caveats (Because There Always Are)
Before you go looking for itaconate supplements online, a few reality checks:
This is preclinical research. Everything I’ve described happened in mice. Mice are a decent model for studying anxiety and neuroinflammation, but they’re not humans. We don’t know yet whether DI would have the same effects in people, what the right dose would be, or whether there are side effects.
DI isn’t a magic bullet. It didn’t completely erase anxiety in infected mice—it reduced it significantly, but the mice weren’t “cured.” Also, DI didn’t reduce the parasite load. If you have a T. gondii infection and it’s causing symptoms, you’d still need antiparasitic treatment.
The Acod1/itaconate axis is complex. It’s not as simple as “more itaconate = less anxiety.” In some contexts, itaconate might have different effects. The timing matters (prevention vs. treatment), the dosage matters, and the specific brain region matters.
We still don’t fully understand chronic T. gondii in humans. The epidemiological links between T. gondii and anxiety are suggestive but not definitive. Not everyone with T. gondii antibodies has anxiety, and not everyone with anxiety has T. gondii. It’s likely one piece of a much larger puzzle.
What’s Next?
The research team behind this study has opened a door, but there’s a lot of work left to do. Some key questions for future research:
Can we develop itaconate-based therapies that are safe and effective in humans?
Are there other metabolites or immune-metabolic pathways that influence anxiety in similar ways?
Could we identify biomarkers (like IDO levels or itaconate levels) to predict who might benefit from this kind of treatment?
How does this mechanism interact with other known drivers of anxiety, like chronic stress or early-life trauma?
There’s also the tantalizing possibility of repurposing existing drugs. Sulforaphane, for instance, is already available as a dietary supplement and has been studied for neuroprotective effects. Could it (or similar Nrf2 activators) eventually find a place in the treatment of infection-associated neuropsychiatric conditions?
The Bottom Line
The idea that a parasite most of us carry could be influencing our mood is, frankly, wild. But the science is starting to back it up. What this latest research adds is a detailed mechanistic understanding: chronic T. gondii infection drives anxiety by triggering neuroinflammation in the amygdala, and that inflammation is mediated—at least in part—by the Acod1/itaconate axis.
More importantly, it shows that we might be able to interrupt that process. By targeting the immune-metabolic machinery of the brain—rather than just the symptoms—we could be looking at a new wave of treatments for anxiety and other neuropsychiatric disorders.
Will itaconate derivatives become the next SSRIs? Almost certainly not in the near future. But the research underscores a profound point: mental health isn’t just about neurotransmitters. It’s about immunity, metabolism, and the intricate dance between the two. And as we unravel those connections, we get closer to therapies that actually address the root causes of suffering—not just mask the symptoms.
If you’ve been struggling with anxiety and conventional treatments haven’t helped, it’s worth talking to a knowledgeable healthcare provider about whether underlying inflammation or infection could be playing a role. Science is moving fast, and what sounds like science fiction today might be a standard lab test five years from now.
Have thoughts or questions about the parasites-anxiety connection? Drop them in the comments below—I’d love to hear from you.